What is ImmuCell?
ImmuCell Corporation is dedicated to enhancing the health and productivity of dairy and beef cattle through scientifically validated products. The company is known for its First Defense® line, which offers immediate immunity to newborn calves. Furthermore, ImmuCell is advancing the development of Re-Tain®, a groundbreaking treatment for subclinical mastitis in dairy cows that aims to provide an alternative to traditional antibiotics without requiring milk discard.
How much funding has ImmuCell raised?
ImmuCell has raised a total of $32.6M across 8 funding rounds:
Stock Offering
$5.9M
Share Placement
$3.5M
Multiple Rounds
$10.3M
Stock Offering
$8.3M
Debt
$350K
Share Placement
$4.3M
Stock Issuance/Offering (2016): $5.9M with participation from Undisclosed
Share Placement (2016): $3.5M led by Undisclosed
Debt (2017): $6.5M supported by TD Bank N.A
Private Equity (2017): $1.1M featuring Brian L. Pessin and Sandra F. Pessin
Stock Issuance/Offering (2017): $2.7M backed by Craig-Hallum Capital Group
Stock Issuance/Offering (2019): $8.3M with participation from Craig-Hallum Capital Group
Debt (2020): $350K led by PPP
Share Placement (2021): $4.3M, investors not publicly disclosed
Key Investors in ImmuCell
Craig-Hallum Capital Group
Craig-Hallum Capital Group is an investment bank that provides financial advisory and capital markets services. Their involvement suggests a strategic financial backing for ImmuCell's growth initiatives.
TD Bank N.A
TD Bank N.A. is a major financial institution offering a wide range of banking and financial services. Their participation indicates a debt financing component supporting ImmuCell's operational and developmental needs.
Brian L. Pessin
Brian L. Pessin is an individual investor who has participated in ImmuCell's funding rounds. His investment suggests a personal stake in the company's mission and potential.
What's next for ImmuCell?
The recent major strategic investment in ImmuCell signals a strong confidence in its product pipeline and market strategy. This capital infusion is expected to accelerate the development and commercialization of Re-Tain®, potentially disrupting the current antibiotic-dependent treatments for mastitis. The company's focus on immediate immunity for calves and novel mastitis treatments positions it for significant growth and influence within the livestock health industry.
See full ImmuCell company page
